$3.98
-0.09 (-2.21%)
Open$4.10
Previous Close$4.07
Day High$4.20
Day Low$3.97
52W High$7.82
52W Low$2.77
Volume—
Avg Volume759.9K
Market Cap223.69M
P/E Ratio—
EPS$-1.35
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+488.9% upside
Current
$3.98
$3.98
Target
$23.44
$23.44
$15.10
$23.44 avg
$28.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 193.62M | 202.51M | 206.29M |
| Net Income | -27,587,371 | -28,749,471 | -33,771,699 |
| Profit Margin | -14.3% | -14.2% | -16.4% |
| EBITDA | -51,862,975 | -48,122,998 | -52,884,989 |
| Free Cash Flow | -39,587,712 | -47,283,878 | -36,549,207 |
| Rev Growth | +24.4% | +2.2% | +1.5% |
| Debt/Equity | 0.26 | 0.22 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |